Table 1.
Clinical, treatments, and outcome characteristics of confirmed COVID-19 patients.
| Characteristics | Overall (n = 9) | Favipiravir (Avigan) (n = 3) | Lopivia (n = 3) | Remdesivir (n = 3) |
|---|---|---|---|---|
| Gender | ||||
| Male | 4 (44.44) | 0 (0.00) | 2 (66.67) | 2 (66.67) |
| Female | 5 (55.56) | 3 (100.00) | 1 (33.33) | 1 (33.33) |
| Age | 54.56 ± 14.46 | 59.67 ± 11.59 | 57.33 ± 14.74 | 46.67 ± 14.19 |
| Clinical symptoms | ||||
| Shortness of breath | 7 (77.78) | 2 (66.67) | 2 (66.67) | 3 (100.00) |
| Cough | 7 (77.78) | 3 (100.00) | 2 (66.67) | 2 (66.67) |
| Fever | 5 (55.56) | 2 (66.67) | 1 (33.33) | 2 (66.67) |
| Anosmia | 2 (22.22) | 0 (0.00) | 1 (33.33) | 1 (33.33) |
| Diarrhea | 0 (0.00) | 0 (0.00) | 0 (0.00) | 0 (0.00) |
| Nausea & vomiting | 2 (22.22) | 0 (0.00) | 2 (66.67) | 0 (0.00) |
| Comorbidities | ||||
| Obesity | 2 (22.22) | 0 (0.00) | 1 (33.33) | 1 (33.33) |
| Type 2 diabetes mellitus | 5 (55.56) | 2 (66.67) | 1 (33.33) | 2 (66.67) |
| Hypertension | 4 (44.44) | 2 (66.67) | 2 (66.67) | 0 (0.00) |
| Laboratory examination | ||||
| ALT (IU/L) | 50.88 ± 33.10 | 47.50 ± 10.61 | 70.67 ± 56.59 | 33.33 ± 1.15 |
| AST (IU/L) | 54.00 ± 26.32 | 42.00 ± 16.97 | 77.00 ± 35.00 | 39.00 ± 11.27 |
| Albumin (g/dL) | 3.39 ± 0.21 | 3.45 ± 0.07 | 3.39 ± 0.18 | 3.35 ± 0.37 |
| Total bilirubin (mg/dL) | 0.56 ± 0.27 | 0.22 ± 0.00 | 0.72 ± 0.30 | 0.59 ± 0.16 |
| Direct bilirubin (mg/dL) | 0.31 ± 0.19 | 0.14 ± 0.00 | 0.45 ± 0.28 | 0.22 ± 0.06 |
| Neutrophil (%) | 75.37 ± 13.47 | 80.35 ± 5.73 | 74.03 ± 19.74 | 76.70 ± 12.20 |
| Lymphocytes (%) | 15.76 ± 8.52 | 14.35 ± 6.58 | 15.50 ± 13.08 | 16.97 ± 9.65 |
| NLR (%) | 21.02 ± 45.05 | 6.36 ± 2.35 | 45.95 ± 74.78 | 5.86 ± 3.76 |
| APTT (sec) | 28.06 ± 5.21 | 28.45 ± 0.21 | 31.50 ± 5.09 | 20.4 ± 0.00 |
| PTT (sec) | 11.20 ± 1.62 | 12.10 ± 2.55 | 10.60 ± 1.13 | 10.6 ± 0.00 |
| CRP (mg/dL) | 12.27 ± 15.34 | 7.20 ± 3.61 | 16.67 ± 14.52 | 3.65 ± 5.02 |
| D-dimer (ng/dL) | 1861.29 ± 1828.85 | 900.00 ± 480.83 | 1655.00 ± 332.34 | 2639.67 ± 2826.26 |
| Procalcitonin (ng/dL) | 1.54 ± 2.84 | 0.17 ± 0.00 | 5.18 ± 0.00 | 0.1 ± 0.1 |
| Treatment | ||||
| Levofloxacin | 4 (44.44) | 1 (33.33) | 0 (0.00) | 3 (100.00) |
| Moxifloxacin | 1 (11.11) | 0 (0.00) | 1 (33.33) | 0 (0.00) |
| Ceftriaxone | 1 (11.11) | 0 (0.00) | 1 (33.33) | 0 (0.00) |
| Paracetamol | 4 (44.44) | 2 (66.67) | 1 (33.33) | 1 (33.33) |
| N-acetylcysteine | 7 (77.78) | 3 (100.00) | 2 (66.67) | 2 (66.67) |
| Curcuma | 4 (44.44) | 1 (33.33) | 3 (100.00) | 0 (0.00) |
| Albumin | 6 (66.67) | 2 (66.67) | 1 (33.33) | 3 (100.00) |
| Dexamethasone | 5 (55.56) | 1 (33.33) | 1 (33.33) | 3 (100.00) |
| Outcome | ||||
| Length of stay (days) | 28.11 ± 20.81 | 38.33 ± 30.98 | 26.33 ± 21.38 | 19.66 ± 6.80 |
| Death | 1 (11.11) | 0 (0.00) | 1 (33.33) | 0 (0.00) |